Genomic diagnostics company Veracyte Inc (Nasdaq:VCYT) stated on Tuesday that it recorded a net loss of USD0.7m for the third quarter ended 30 September 2019.
This marks an improvement of improvement of 84% from net loss of USD4.47m the same prior year quarter.
Net loss per share of USD0.02 was recorded for the third quarter ended 30 September 2019, a rise of 83% from net loss per share of 0.12 in the comparable year quarter.
Revenue of USD31.0m was generated for the third quarter of 2019, up 32% over the revenues of USD23.4m in the third quarter of 2018.
Research and development expenses of USD3.6m and USD3.4m were announced for the third quarters of 2019 and 2018 respectively.
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Perrigo to pay quarterly dividend of USD0.290 per share
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline